Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial

A global phase 3 study evaluated the pharmacokinetics, efficacy and safety of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 27 previously treated male children (1–11 years) with severe and moderately severe haemophilia B (factor IX [FIX] activity ≤2 IU/dl). All...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenet, Gili, Chambost, Hervé, Male, Christoph, Lambert, Thierry, Halimeh, Susan, Chernova, Tatiana, Mancuso, Maria Elisa, Curtin, Julie, Voigt, Christine, Li, Yanyan, Jacobs, Iris, Santagostino, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Schattauer 2016
Materias:
Coagulation and Fibrinolysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039316/
https://www.ncbi.nlm.nih.gov/pubmed/27583313
http://dx.doi.org/10.1160/TH16-03-0179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039316/
https://www.ncbi.nlm.nih.gov/pubmed/27583313
http://dx.doi.org/10.1160/TH16-03-0179

Ejemplares similares